Welcome to our dedicated page for Protara Therapeutics news (Ticker: TARA), a resource for investors and traders seeking the latest updates and insights on Protara Therapeutics stock.
Protara Therapeutics, Inc. (Nasdaq: TARA) is a clinical-stage biotechnology company developing therapies for cancer and rare diseases, and its news flow reflects progress across its investigational programs. Company announcements frequently highlight updates on TARA-002, an investigational cell-based therapy in development for non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs), as well as on IV Choline Chloride, an investigational phospholipid substrate replacement therapy for patients on long-term parenteral support.
Investors following TARA news can expect detailed coverage of clinical trial milestones, including interim data from the Phase 2 ADVANCED-2 trial in NMIBC and the Phase 2 STARBORN-1 trial in pediatric LMs. Recent press releases have discussed complete response rates, safety and tolerability findings, and regulatory feedback from the U.S. Food and Drug Administration (FDA) on potential registrational paths for TARA-002 in both BCG-unresponsive and BCG-naïve NMIBC populations.
News items also report on regulatory designations and programs, such as Breakthrough Therapy, Fast Track, and Rare Pediatric Disease designations for TARA-002 in LMs, and Fast Track and Orphan Drug Designations for IV Choline Chloride in patients on long-term parenteral nutrition. In addition, Protara’s releases describe participation of TARA-002 in the FDA’s Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) Program.
Another key theme in TARA news is capital markets activity, including underwritten public offerings of common stock under the company’s shelf registration statement on Form S-3, with proceeds directed toward the clinical development of TARA-002 and other programs. Corporate updates may reference conference presentations, such as appearances at healthcare conferences, and scheduled webcasts to review new clinical data.
By monitoring this news page, readers can follow Protara’s disclosed clinical data updates, regulatory interactions, financing events, and other material developments that the company reports through press releases and related communications.
Protara Therapeutics (TARA) announced the appointment of Barry P. Flannelly, Pharm.D, to its Board of Directors, replacing Scott Braunstein, M.D. Dr. Flannelly brings over 20 years of experience in the pharmaceutical and biotech sectors, currently serving as Executive Vice President at Incyte. CEO Jesse Shefferman expressed optimism about leveraging Dr. Flannelly's expertise to advance Protara's lead program, TARA-002, aimed at treating lymphatic malformations. The transition occurs at a pivotal time for Protara as it seeks to enhance its drug development pipeline.
Summary not available.
Protara Therapeutics (Nasdaq: TARA) announced the grant of inducement stock options for 3,700 shares to a new employee, with an exercise price of $28.20, matching the closing price on July 1, 2020. The options will vest over four years, with 25% vesting after one year and the remainder monthly thereafter, contingent on continued employment. This move aligns with NASDAQ Listing Rule 5635(c)(4) and indicates Protara's commitment to attracting talent essential for advancing its clinical programs aimed at treating rare diseases.
Protara Therapeutics (Nasdaq: TARA) announced the grant of inducement non-qualified stock options for 3,700 shares to a new employee. The exercise price is set at $51.12, equivalent to Protara's closing price on June 1, 2020. The options will vest over four years, with 25% cliff vesting on the first anniversary, followed by monthly vesting. The award aligns with NASDAQ Listing Rule 5635(c)(4) and is designed to attract talent for Protara's focus on rare diseases, including TARA-002 for lymphatic malformations and IV choline chloride for intestinal failure-associated liver disease.
Protara Therapeutics, previously ArTara Therapeutics, has announced its name change effective immediately, with shares continuing to trade under the ticker symbol TARA. The rebranding aims to enhance the company's identity and commitment to developing innovative therapies for rare diseases. Its lead drug candidate, TARA-002, targets lymphatic malformations and is based on OK-432, a treatment approved in Japan and Taiwan. Protara also has IV Choline Chloride as a Phase 3-ready therapy for patients with intestinal failure associated liver disease. A new corporate website has been launched.
ArTara Therapeutics (TARA) announced the grant of inducement stock options totaling 4,100 shares to two new employees at an exercise price of $24.02 per share, equivalent to the May 1, 2020 closing price. These options will vest over four years, with 25% vesting after one year and the remainder monthly thereafter. The Compensation Committee approved these awards in line with NASDAQ Listing Rule 5635(c)(4). ArTara focuses on developing treatments for rare diseases, including TARA-002 for lymphatic malformations and IV choline chloride for intestinal failure-associated liver disease.